Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes

Novo Nordisk

Status: Completed

Conditions: Diabetes Mellitus, Type 1; Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin detemir; Drug: biphasic insulin aspart 30

Study type: Observational

Funder types: Industry

Identifiers

NCT00671008

NN304-1964

Details and patient eligibility

About

This trial is conducted in Europe.

The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.

Enrollment: 400 patients

Sex: All

Ages: 6+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Type 1 or Type 2 diabetes, including newly diagnosed
• Age: Levemir® above 6 years
• Age: Novomix® above 18 years

Exclusion criteria

• Current treatment with NovoMix® 30 or Levemir®

Trial design

400 participants in 2 patient groups

A

Treatment:

Drug: biphasic insulin aspart 30

B

Treatment:

Drug: insulin detemir